FROM TRANSFORMATIONAL TECHNOLOGIES TO INNOVATIVE HEALTH CARE SOLUTIONS

The 2019 CSPS Symposium is coming soon and promises to be another amazing event with fantastic speakers and sessions!

**Some of this year's exciting topics:**
- 3D printing,
- Radiopharmaceuticals for Diagnosis and Therapy
- Medical Cannabis: Nexus of Science
- Regulation and Patient Rights
- Artificial Intelligence in Research and more!

The symposium will take place on **May 21-24th** at the Sheraton Vancouver Airport Hotel.

We hope to see you there!
The CSPS Young Scientist Network (CSPS-YSN) was launched at the 2018 CSPS symposium held in Toronto and has connected trainees from all over Canada via our online newsletters and Twitter page (@CSPS_YSN). Our newsletters have not only given us an insight into the different research projects that are ongoing all over Canada but was also a platform for the leading researchers and professors in Canada to share their advice and tips for success!

We have also had the opportunity to interview some of the new up-and-coming researchers and learn about their PhD and Master's projects. We invite you to join us to celebrate success and raise awareness of the most recent publications and exciting projects that are happening all around Canada!

It has been a great first year for the CSPS-YSN and we hope to continue this success and to grow this network even more in 2019. The CSPS-YSN have arranged a Trainee-Mentor breakfast on Wednesday May 22nd from 7-9am. We have invited amazing speakers who are experts in their fields, representing academia, industry and government. This breakfast will provide trainees with the opportunity to ask questions and learn from the experts. Our mentors attending the breakfast include: Christine Allen, Marcel Bally, Reina Bendayan, Ron Boch, Noriko Daneshtalab, Marc Gauthier, Shawn Glinter, Agnes Klein, and Cathy Lau (biographies below).

We have arranged a networking evening on Wednesday May 22nd from 6 - 7:30pm. This will be an amazing opportunity to connect with trainees from across Canada and discuss how we can continue to grow and improve the CSPS-YSN.

We have also put together a Lunch and Learn for trainees on Thursday May 23rd from 12:30-1:30pm. We have invited special guest Helen Burt to come to talk to all the trainees and share her secrets for success and to tell us about her career journey.

We are very excited to catch up with everyone at the symposium and look forward to seeing you there!
THE CSPS YOUNG SCIENTIST NETWORK PRESENTS

TRAINEE BREAKFAST

FEATURING MENTORS FROM ACADEMIA, INDUSTRY & GOVERNMENT!

WEDNESDAY MAY 22, 2019
7-9AM - WESTMINSTER ROOM
BREAKFAST PROVIDED

CONTACT CSPS.YSN@GMAIL.COM FOR MORE DETAILS
THE CSPS YOUNG SCIENTIST NETWORK PRESENTS

YSN TRAINEE NETWORKING EVENING

WEDNESDAY MAY 22, 2019
6:00-7:30PM - MINORU ROOM
REFRESHMENTS PROVIDED

CONNECT WITH FELLOW TRAINEES IN PHARMACEUTICAL SCIENCES FROM ACROSS CANADA

CONTACT CSPS.YSN@GMAIL.COM FOR MORE DETAILS
Young Scientist Network Presents

TRAINEE LUNCH & LEARN

DR. HELEN M. BURT
Faculty of Pharmaceutical Sciences
University of British Columbia

CSPS 2019
Thursday May 23rd, 2019
12:30-1:30PM
WESTMINSTER ROOM
Lunch Provided
NORIKO DANESHTALAB

Dr. Daneshtalab graduated from University of Alberta with her PhD in Pharmaceutical Sciences; 2005. She completed two post-doctorates, first in John P. Robarts institute for research in London, Ontario and second in Memorial University of Newfoundland. She is currently an Associate Professor at Memorial University of Newfoundland in the School of Pharmacy. Her research areas include studying Mechanisms of cerebrovascular dysfunction associated with chronic inflammation (particularly autoimmune disease) leading to stroke development, role of diet and inflammation in promoting therapeutic failure in cardiovascular disease outcomes, and multi-disease models including arthritis and cardiovascular complications. Her teaching areas are basic and clinical pharmacokinetics and pharmacodynamics, general pharmacology in the three teaching tracks (basic undergraduate, PharmD, and the working professional program).

RON BOCH

Dr. Ron Boch is the Vice President, Biotechnology and Industry Affairs with lead responsibility for BIOTECanada’s industry policy development. Before joining BIOTECanada, Ron was the Director, Pharmaceutical Development at Variation Biotechnologies Inc. He is experienced in chemistry, manufacturing and controls particularly regarding biotechnology products and formulation. Prior to VBI, Ron worked at QLT Inc. in Vancouver for over ten years where he contributed to the development of Visudyne (approved for the treatment of age-related macular degeneration) and as the Associate Director, Formulation, he directed the development activities of a wide variety of preclinical and clinical products. As a named inventor of over 60 US and international patent applications including nine different patent families, Ron developed technologies for new business opportunities and managed relationships with key opinion leaders.
CHRISTINE ALLEN

Christine Allen is a Professor and the GSK Chair in Pharmaceutics and Drug Delivery in the Leslie Dan Faculty of Pharmacy at the University of Toronto. She is also currently serving as interim Dean and previously served as the Associate Dean Academic and Associate Dean Graduate Education. Dr. Allen’s research is focused on the design and development of new materials and technologies for the delivery of drugs and contrast agents. She has received career awards from CIHR-Rx&D, CSPS and AFPC. She is co-founder and President of Nanovista Inc., a start-up housed in JLabs, which is focused on the development of multimodal contrast agents to improve the performance of image-guided high precision cancer therapy. Christine is the President Elect of CSPS and a member of the Governing Council of NSERC.

Prof. Marc A. Gauthier obtained his PhD in polymer chemistry from the Université de Montréal in 2007. Following a postdoc at the Swiss Federal Institute of Technology Lausanne (EPFL), he became a Research Associate at the Swiss Federal Institute of Technology Zurich (ETHZ) in 2009. In 2013 he joined the faculty of the Institut National de la Recherche Scientifique (INRS) in Canada where his work is focused on developing new types of dynamic covalent bonds, designing therapeutic protein–polymer conjugates, establishing new technologies for drug discovery, and investigating new opportunities for physically actuating therapeutic bioconjugates.
Dr. Klein is currently the Senior Medical Advisor to the Director General, Biologic and Genetic Therapies Directorate, Health Canada. Until the beginning of 2017, Dr. Klein was the Director, Centre for the Evaluation of Radiopharmaceuticals and Biotherapeutic Products in the same Directorate. After receiving her medical degree from the University of Toronto, Dr. Klein trained in Endocrinology, Medical Biochemistry and Public and Community Health. After joining Health Canada, she has occupied many and varied positions, scientific and managerial. Amongst relevant accomplishments, Dr. Klein represented Health Canada on NCBHR, as founding member and NCEHR as well as chairing the Committee on Clinical Trials of the Council. In 2000, Dr. Klein moved to Biologics where she actively participated in the inception of the new Directorate and its processes. Dr. Klein was an active participant in the CIOMS document on Pharmacogenetics and Pharmacoeconomics as well as in the ICH process drafting of guidelines (ICH E15, E16 and most recently E18, all on pharmacogenomics aspects of drug development). In addition to her special interest in biomarkers, surrogate endpoints and the appropriate design of clinical trials, especially the issues related to small studies, Dr. Klein is also interested in the regulatory and clinical issues regarding subsequent entry biologics (SEBs). This interest has included authorship and co-authorship of several articles on biosimilars. Dr. Klein has made numerous presentations to professional and regulatory groups on issues surrounding the ethics of clinical trials and the integrity of clinical trial data. Dr. Klein has also presented on a wide-variety of new regulatory endeavours, including biosimilars. Dr. Klein has also been involved actively with the various meetings organized through the Drug Information Association. More recently, Dr. Klein has helped to organise a workshop on Progress in Diabetes in conjunction with the JDRS and forms part of an International Consortium on Clinical Trials in Neonatology. Dr. Klein is an active supporter for excellence in the development of medicines. As such Dr. Klein has been closely involved in the drafting of guidelines for the development and review a guidance on the development of drugs in rare diseases as well as for biosimilars. Dr. Klein had been the recipient of an Award of Excellence from DIA, several years ago. In 2017, Dr. Klein received the Founders’ Award from the Regulatory Affairs Professional Society at the Annual Convergence in Washington, D.C.
This year more than 78,000 Canadians will die of cancer and deaths due to cancer are almost always attributed the complications caused by metastatic disease. As an independent researcher with experience in academia and industry, Dr. Bally has focused his career on development of much needed novel drugs, drug combinations and drug delivery systems designed for use in patients with metastatic cancer. Dr. Bally received his BSc (1977) and MSc (1979) degrees in biology from Texas A&M University. He obtained his PhD from the Department of Biochemistry at the University of British Columbia (1984). He has recognized expertise in biochemistry, pharmacology/toxicology, drug formulations and preclinical cancer models. He is qualified to conduct preclinical safety studies under Good Laboratory Practices (GLP) and has completed training in Good Manufacturing Practices. He has generated >550 scientific articles, abstracts, book chapters and patents that have been cited >22,000 times. He has trained >60 highly qualified personnel; many of which now hold significant positions in industry, academia and medicine. He has been a PI/Co-PI on grants valued at >$60M and he has participated in private sector funding for companies that he co-founded including Lipex (acquired by Northern Lipids), Inex (now Arbutus), Northern Lipids (renamed Transferra and purchased by Evonik in 2016), Celator (purchased by Jazz in 2016) and Cuprous, founded recently, which is focused on developing small molecule immunotherapeutics for cancer. To date this effort resulted in three marketed drugs (Myocet- for metastatic breast cancer; Marqibo- for relapsed ALL and CPX-351 (VYXEOS) which some believe will replace the standard of care for high risk AML).
Dr. Reina Bendayan is a Professor, Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto. After obtaining a Bachelors of Sciences in Pharmacy and a Hospital Pharmacy Residency Program at the University of Montreal, Dr. Bendayan completed a Doctor of Pharmacy at the University of Florida and a three year Medical Research Council Post-Doctoral Fellowship Program in Clinical Pharmacology and Membrane Cell Biology at the University of Toronto. Dr. Bendayan’s research program at the University of Toronto is primarily focused on Membrane Transport and Therapeutics with an emphasis in the field of HIV/AIDS Antiviral Drug Transport and Regulation in the central nervous system. She obtained a five-year young career investigator award from the Ministry of Health of Ontario and her research program is primarily funded by the Canadian Institutes of Health Research, Canadian Foundation for AIDS Research and the Ontario HIV Treatment Network, Ministry of Health of Ontario. She is the author of over 70 peer-reviewed manuscripts and has supervised many graduate students and post-doctoral research fellows. She is a member of several scientific associations, in particular, the American Association for the Advancement of Sciences (AAAS), American Society of Pharmacology and Experimental Therapeutics (ASPET), American Association of Pharmaceutical Sciences (AAPS), International Blood-Brain Barrier Society (IBBS), International AIDS Society and Canadian Society of Pharmaceutical Sciences (CSPS). Dr. Bendayan has recently been elected FELLOW of the American Association of Pharmaceutical Sciences (November 2010) and is the recipient of a five-year Career Scientist Award from the Ontario HIV Treatment Network, Ministry of Health of Ontario. Dr. Bendayan served as Graduate Coordinator (1998-2003), Chair and Associate Dean Graduate Education of the Graduate Department of Pharmaceutical Sciences (July 2005-July 2011) and as Acting Dean of the Leslie Dan Faculty of Pharmacy (January 2007-July 2007).
Shawn’s career began in emergency medicine and hospital administration (George Washington University Health System and MedStar Health in Washington, DC, and Vanderbilt University in Nashville, TN). He then launched a SAAS startup focused around the utilization of AED’s and the implementation of Public Access Defibrillation Programs. Not long after that, he started a technology company, which sold to a firm in Silicon Valley. After a couple of false starts and several successful startups, Shawn became a founding partner in a medical reimbursement company that ran out of gas... Through that experience, Shawn learned a lot about himself and entrepreneurship as well. Most recently, Shawn was a co-founder & CEO of a life sciences (water technology) company for an entity located in the USA, Canada, and Europe. In just over 3.5 years he successfully grew that company from $600K to 11M (which eventually sold). Shawn is currently the Founder & CEO of the biotechnology startup Pendant Biosciences (formerly Nanoferix) an advanced materials company developing innovative surface coating and drug delivery technologies using a unique, polymer-based platform. The company is initially focused on applications within the orthopedic market, and its lead product candidate is a surface modification intended to reduce the risk of infection associated with certain orthopedic implants. Pendant is currently a Johnson & Johnson Innovations JLABS Company. Shawn recently received a Faculty appointment at the University of Louisville, Schools of Medicine, in the Department of Neurological Surgery, as the Director of Innovation & Entrepreneurship. Shawn is currently the Entrepreneur in Residence at Belmont University and a Mentor in Residence at Vanderbilt University in Nashville, TN. Shawn has spent the last eight years as one of the Master Mentors at the Nashville Entrepreneur Center. He also a mentors for the Life Science Tennessee Mentor Program, the JumpStart Foundry, the Co.Lab accelerator program in Chattanooga, and is a Master Mentor for Launch TN (a state wide accelerator program).
Currently VP of Regulatory Affairs and Quality at Janssen Canada (a J&J company) Catherine was a graduate of Yale University with a PhD in Molecular Biology and Biochemistry and a post-doctoral fellow of Princess Margaret Hospital focusing on cancer research. Catherine joined Johnson & Johnson to head Discovery Research and was made Director of the research unit in 1988, heading a group of 40 research scientists focusing on oncology, immunology and metabolism in drug discovery. After completing over 50 publications in basic science, Catherine moved to head the Clinical research group and was made Senior Director of Clinical Research 1999. From 2006 onwards, she was made Vice-President of Regulatory Affairs. Catherine has published over 70 papers in reputable scientific journals and was made of member of Who’s Who Canada and International. Catherine was elected to the role of President Elect of Canadian Society of Pharmaceutical Sciences in 2016 and is the president from 2018 to 2019. Catherine, as a member of Biotech Canada has been working with Health Canada in determining the scientific standards (pharmacokinetic and clinical) and regulatory requirements most pertinent to the approval of Biosimilars in Canada. Also as a key member of Canadian IMC, the Canadian Organization for Innovative Medicine, Catherine is instrumental in assisting the drafting of the Canadian Orphan Drug Framework and Regulation and other policies important for regulatory reform in Canada. The most recent appointment on January 2019 was to be the industry representative for the Real World Evidence Core Action Team which is the national advisory committee chaired jointly by Health Canada and CADTH. In this role, Catherine provides advice to the Core Team and also acts as the conduit for the innovative sector of the pharmaceutical business.
Dr. Burt is the Associate Vice-President Research & Innovation and has served in the Office of Vice President Research & Innovation (formerly Research & International) since 2011. She was born in Manchester, England and obtained her B. Pharm. (Hons) from the University of Bath and her Ph.D in Pharmaceutics from UBC. In her role as Angiotech Professor of Drug Delivery in UBC’s Faculty of Pharmaceutical Sciences, Dr. Burt’s major research efforts are supported by grants from CIHR and NSERC and involve the development of polymer-based drug delivery systems, in particular micro- and nanoparticulates, for controlled and localized drug delivery. She has published over 150 peer-reviewed papers and 8 patents and has been the recipient of several teaching prizes and research awards, including the UBC Killam Teaching Prize and Killam Faculty Research Prize, NSERC Synergy Award for Innovation, CSPS Award of Leadership in Canadian Pharmaceutical Sciences and YWCA Woman of Distinction Award for Science, Research and Technology. She is a founding scientist in the Centre for Drug Research and Development (CDRD), a member of the Canadian Academy of Health Sciences and has served on the Board of Directors of the Provincial Health Services Authority.